The Gulf South Minority/Underserved ? NCORP (GS-M/U-NCORP) and the Ochsner-Community-NCORP, the two NCORPs in Louisiana, have both met the objectives proposed for the last funding cycle, expanding access to and significantly increasing the number of patients participating in clinical trials in Louisiana and the Gulf South region. These successful NCORPs have agreed to come together to form the Gulf South Minority/Underserved Clinical Trials Network (Gulf South M/U CTN) NCORP, which will have as its primary affiliates the LSU ? Cancer Center New Orleans (LSU-CC-New Orleans), LSU ? Feist Weiller Cancer Center Shreveport (LSU-FWCC-Shreveport), Mary Bird Perkins Cancer Center (MBPCC) and the Ochsner-Cancer Center (Ochsner). The new Gulf South M/U CTN will provide cancer care and access to clinical trials for >50% of new cancer cases in the region, expand the number of sites offering access to clinical trials from 22 to 42, and exceed the required 30% proportion of minority patients participating in NCORP trials. The Gulf South M/U CTN will bring additional resources including the Louisiana Tumor SEER registry (LTR-SEER) and the state-wide cancer screening programs such as the Louisiana Breast and Cervical Health Program (LBCHP), and the Louisiana Comprehensive Cancer Control Program (LCCCP). In addition we will benefit from ongoing research led by our investigators and aimed at understanding cancer inequities and disparities in our region. The new Gulf South M/U CTN has also expanded its network with major health providers in the region including the Veterans Administration Hospital (New Orleans), Woman's Hospital (the largest dedicated clinical center for women's health) in Baton Rouge and the Christus Health community sites. The new Gulf South M/U CTN has garnered the support of the Louisiana Department of Health Secretary and the Governor, who are developing a cancer care plan for the state (Taking Aim at Cancer in Louisiana Collaborative -TACL), where the Gulf South M/U CTN is the major provider of state-wide cancer clinical trials. This support will help us to continue increasing the participation of patients in NCORP and non-NCORP studies. To achieve our goals we will implement the following three strategies. 1. Expand the number of sites through additional partnerships with community organizations such as FQHC's where we will test novel approaches to increase the participation of community physicians providing care to cancer patients in the region; 2. Support the development of CCDR and Health Disparities research initiated by our investigators to understand the inequities created by cancer in our region and 3. Increase our participation in national trials supported by NCORP and other organizations to expand the scope and depth of trials offered to our patients.

Public Health Relevance

The Gulf South M/U Clinical Trials network brings together the strengths of the two NCORPs of Louisiana. This will double the number of sites offering clinical trials in the Gulf South. We will explore new approaches to increase the participation of minority-underserved patients and community physicians in cancer clinical trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Lee, Cecilia H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Louisiana State Univ Hsc New Orleans
Internal Medicine/Medicine
Schools of Medicine
New Orleans
United States
Zip Code
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Puvvada, Soham D; Li, Hongli; Rimsza, Lisa M et al. (2016) A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma 57:2359-69
Press, Oliver W; Li, Hongli; Schöder, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7

Showing the most recent 10 out of 11 publications